Eli Lilly LLY Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Jardiance | $3.53B-3.7% | $3.43B+2.7% | $3.86B+31.3% | $3.59B+21.4% | $3.67B+28.5% | |
| Mounjaro | $27.79B+105% | $22.97B+99.0% | $19.09B+86.8% | $15.68B+84.3% | $13.58B+112% | |
| Neuroscience | $1.5B+10.6% | $1.39B-5.6% | $1.33B-8.2% | $1.36B-52.4% | $1.36B-53.3% | |
| Other cardiometabolic health | $3.97B-9.4% | $4.01B-10.2% | $4.21B-42.4% | $4.19B-34.4% | $4.38B-18.4% | |
| Other immunology | $1.83B+48.7% | $1.68B+48.6% | $1.53B-14.4% | $1.38B-7.9% | $1.23B-1.3% | |
| Other oncology | $3.83B+10.2% | $3.65B+6.0% | $3.65B-21.3% | $3.57B-10.4% | $3.48B+2.9% | |
| Taltz | $3.53B+3.4% | $3.56B+9.3% | $3.46B+11.9% | $3.44B+16.3% | $3.42B+20.5% | |
| Trulicity | $4.1B-16.2% | $4.28B-18.6% | $4.49B-20.8% | $4.74B-21.6% | $4.89B-26.0% | |
| Verzenio | $5.87B+8.3% | $5.72B+7.8% | $5.67B+15.9% | $5.57B+22.0% | $5.42B+30.1% | |
| Zepbound | $15.39B+129% | $13.54B+175% | $11.19B+250% | $8.86B+357% | $6.72B+869% | |
| Revenue by Geography | ||||||
| China | $2.19B+26.4% | $1.95B+17.5% | $1.91B+18.5% | $1.81B+17.3% | $1.73B+12.4% | |
| Europe | $12.82B+62.9% | $11.56B+67.0% | $10.91B+87.8% | $9.04B+33.9% | $7.87B+20.6% | |
| Japan | $2.3B+24.2% | $2.13B+17.5% | $2.04B+20.2% | $1.91B+15.4% | $1.85B+12.3% | |
| Outside U.S. | $25.14B+58.8% | $21.7B+47.9% | $19.78B+51.4% | $17.11B+26.1% | $15.83B+22.9% | |
| Rest of world | $7.83B+79.0% | $6.06B+41.8% | $4.93B+25.0% | $4.35B+21.8% | $4.38B+41.0% | |
| U.S. | $47.11B+42.0% | $43.48B+43.1% | $39.64B+42.6% | $36.15B+42.6% | $33.17B+43.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Eli Lilly break its business down?
- Eli Lilly (LLY) reports revenue by product across 10 parts — Jardiance, Mounjaro, Neuroscience, Other cardiometabolic health and Other immunology. Each is extracted from the segment footnotes and tracked over time.
- Where does Eli Lilly's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Eli Lilly's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
